Curanex Pharmaceuticals (CURX) Payables (2024 - 2025)
Curanex Pharmaceuticals' (CURX) quarterly Payables came in at $2426.0 in Q4 2025, down 51.48% YoY from $5000.0 in Q4 2024, and down 97.88% on a QoQ basis from $114489.0 in Q3 2025.
Curanex Pharmaceuticals (CURX) Payables (2024 - 2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 2 years of Payables data on file, last reported at $2426.0 in Q4 2025.
- Quarterly Payables fell 51.48% year-over-year to $2426.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2426.0 (down 51.48% YoY) and the FY2025 annual result came in at $2426.0, down 51.48% from the prior year.
- Payables retreated to $2426.0 in Q4 2025, from $114489.0 in the prior quarter.
- In the past five years, Payables ranged from a high of $114489.0 in Q3 2025 to a low of $269.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Curanex Pharmaceuticals | 6.11 Mn | 1.11 Mn | - | 2,426.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,426.00 |
| Sep 30, 2025 | 114,489.00 |
| Jun 30, 2025 | 269.00 |
| Dec 31, 2024 | 5,000.00 |